Abstract
Historically, high androgen levels have been linked with an increased risk for coronary artery disease (CAD). However, more recent data suggest that low androgen levels are associated with adverse cardiovascular risk factors, including an atherogenic lipid profile, obesity and insulin resistance. The aim of the present study was to evaluate the relationship between plasma sex hormone levels and presence and degree of CAD in patients undergoing coronary angiography and in matched controls. We evaluated 129 consecutive male patients (mean age 58±4 years, range 43–72 years) referred for diagnostic coronary angiography because of symptoms suggestive of CAD, but without acute coronary syndromes or prior diagnosis of hypogonadism. Patients were matched with healthy volunteers. Out of 129 patients, 119 had proven CAD; in particular, 32 of them had one, 63 had two and 24 had three vessel disease, respectively. Patients had significantly lower levels of testosterone than controls (9.8±6.5 and 13.5±5.4 nmol/l, P<0.01) and higher levels of gonadotrophin (12.0±1.5 vs 6.6±1.9 IU/l and 7.9±2.1 vs 4.4±1.4, P<0.01 for follicle-stimulating hormone and luteinizing hormone, respectively). Also, both bioavailable testosterone and plasma oestradiol levels were lower in patients as compared to controls (0.84±0.45 vs 1.19±0.74 nmol/l, P<0.01 and 10.7±1.4 vs 13.3±3.5 pg/ml, P<0.05). Hormone levels were compared in cases with one, two or three vessel disease showing significant differences associated with increasing severity of coronary disease. An inverse relationship between the degree of CAD and plasma testosterone levels was found (r=−0.52, P<0.01). In conclusion, patients with CAD have lower testosterone and oestradiol levels than healthy controls. These changes are inversely correlated to the degree of CAD, suggesting that low plasma testosterone may be involved with the increased risk of CAD in men.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Sorva R, Taskinen MR, Perheentupa J, Nikkila EA . Testosterone substitution increases the activity of lipoprotein lipase and hepatic lipase in hypogonadal males. Atherosclerosis 1988; 69: 191–197.
Jones DB, Higgins B, Billet JS, Price WH, Edwards CR, Beastall GH et al. The effect of testosterone replacement on plasma lipids and apolipoproteins. Eur J Clin Invest 1989; 19: 438–441.
Glueck CJ, Glueck HI, Stroop D, Speirs J, Hamer T, Tracy T . Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men. J Lab Clin Med 1993; 122: 412–420.
Rosano GMC, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 1999; 99: 1666–1670.
Lerner DJ, Kannel WB . Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow up of the Framingham population. Am J Cardiol 1986; 111: 383–390.
Freedman DS, Jacobsen SJ, Barboriak JJ, Sobocinski KA, Anderson AJ, Kissebah AH et al. Body fat distribution and male/female differences in lipids and lipoproteins. Circulation 1990; 81: 1498–1506.
Seidell JC, Cigolini M, Charzewska J, Ellsinger BM, Bjorntorp P, Hautvast JG et al. fat distribution and gender differences in serum lipids in men and women from four European communities. Atherosclerosis 1991; 87: 203–210.
Larsson B, Bengtsson C, Bjorntorp P, Lapidus L, Sjostrom L, Svardsudd K et al. Is abdominal body fat distribution a major explanation for the sex differences in the incidence of myocardial infarction? The study of men born in 1913 and the study in women, Goteborg, Sweden. Am J Epidemiol 1992; 135: 266–273.
Alexandersen P, Haarbo J, Byrjalsen I, Lawaetz H, Christiansen C . Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res 1999; 84 (7): 813–819.
Wu FCW, von Eckardstein A . Androgens and coronary artery disease. Endocr Rev 2003; 24: 183–217.
Malkin CJ, Pugh PJ, Jones RD, Jones TH, Channer KS . Testosterone as a protective factor against atherosclerosis – immunomodulation and influence upon plaque development and stability. J Endocrinol 2003; 178: 373–380.
Wynne FL, Khalil RA . Testosterone and coronary vascular tone: implications in coronary artery disease. J Endocrinol Invest 2003; 26: 181–186.
Deenadayalu VP, White RE, Stallone JN, Gao X, Garcia AJ . Testosterone relaxes coronary arteries by opening the large-conductance, calcium-activated potassium channel. Am J Physiol Heart Circ Physiol 2001; 281: H1720–H1727.
Aversa A, Fierro V, Malizia F, Greco EA, Canale D, Macchia E et al. A double-blind, randomized, placebo-controlled cross-over study on the effects of testosterone (Testogel) plus sildenafil on cavernous arteries and psychological correlates in men with mild hypogonadism and erectile dysfunction. J Sex Med 2006; 3 (s3): 182.
English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS . Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J 2000; 21: 890–894.
Cauley JA, Gutai JP, Kuller LH, Dai WS . Usefulness of sex steroid hormone levels in predicting coronary artery disease in men. Am J Cardiol 1987; 60: 771–777.
Barrett-Connor E, Khaw KT . Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 1988; 78: 539–545.
Yarnell JW, Beswick AD, Sweetnam PM, Riad-Fahmy D . Endogenous sex hormones and ischemic heart disease in men. The Caerphilly Prospective Study. Arterioscler Thromb 1993; 13: 517–520.
De Backer C, Ambrosioni E, Borch-Johnsen K, Brotous C, Cifkova R, Dallougeville J et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prevent Rehabil 2003; 10 (Suppl 1): S1–S78.
Webb CM, Adamson DL, de Zeigler D, Collins P . Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol 1999; 83: 437–439,, A9..
Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P . Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 1999; 100: 1690–1696.
English KM, Steeds RP, Jones TH, Diver MJ, Channer KS . Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 2000; 102: 1906–1911.
Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH Channer KS . Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 2004; 90: 871–876.
Pugh PJ, Jones H, Channer KS . Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J 2003; 24: 909–915.
Rolf C, Nieschlag E . Potential adverse effects of long-term testosterone therapy. Baillieres Clin Endocrinol Metab 1998; 12: 521–534.
Alexandersen P, Haarbo J, Christiansen C . The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis 1996; 125: 1–13.
Hurley BF, Seals DR, Hagberg JM, Goldberg AC, Ostrove SM, Holloszy JO et al. High-density-lipoprotein cholesterol in bodybuilders vs powerlifters. Negative effects of androgen use. JAMA 1984; 252: 507–513.
Thompson PD, Cullinane EM, Sady SP, Chenevert C, Saritelli AL, Sady MA et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989; 261: 1165–1168.
Crist DM, Peake GT, Stackpole PJ . Lipemic and lipoproteinemic effects of natural and synthetic androgens in humans. Clin Exp Pharmacol Physiol 1986; 13: 513–518.
Taggart HM, Applebaum-Bowden D, Haffner S, Warnick GR, Cheung MC, Albers JJ et al. Reduction in high density lipoproteins by anabolic steroid (stanozolol) therapy for postmenopausal osteoporosis. Metabolism 1982; 31: 1147–1152.
Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335: 1–7.
Sih R, Morley JE, Kaiser FE, Perry III HM, Patrick P, Ross C . Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997; 82: 1661–1667.
Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 2647–2653.
Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 1966–1972.
Tenover JS . Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75: 1092–1098.
Elbers JM, Giltay EJ, Teerlink T, Scheffer PG, Asscheman H, Seidell JC et al. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol (Oxford) 2003; 58: 562–571.
Bhasin S . Effects of testosterone administration on fat distribution, insulin sensitivity, and atherosclerosis progression. Clin Infect Dis 2003; 37 (Suppl 2): S142–S149.
Toda T, Toda Y, Cho BH, Kummerow FA . Ultrastructure of newly formed vessels in thrombi. Endothelium formation in human umbilical artery. Acta Pathol Jpn 1984; 34: 529–536.
Bruck B, Brehme U, Gugel N, Hanke S, Finking G, Lutz C et al. Gender-specific differences in the effects of testosterone and estrogen on the development of atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1997; 17: 2192–2199.
Alexandersen P, Haarbo J, Byrialsen I, Lawaetz H, Christiansen C . Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res 1999; 84: 813–819.
Obasanjo IO, Clarkson TB, Weaver DS . Effects of the anabolic steroid nandrolone decanoate on plasma lipids and coronary arteries of female cynomolgus macaques. Metabolism 1996; 45: 463–468.
Elhage R, Arnal JF, Pieraggi MT, Duverger N, Fievet C, Faye JC et al. 17 Beta-estradiol prevents fatty streak formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 1997; 17: 2679–2684.
Von Dehn G, von Dehn O, Volker W, Langer C, Weinbauer GF, Behre HM et al. Atherosclerosis in apolipoprotein E-deficient mice is decreased by the suppression of endogenous sex hormones. Horm Metab Res 2001; 33: 110–114.
Larsen BA, Nordestgaard BG, Stender S, Kjeldsen K . Effect of testosterone on atherogenesis in cholesterol-fed rabbits with similar plasma cholesterol levels. Atherosclerosis 1993; 99: 79–86.
Adams MR, Williams JK, Kaplan JR . Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness. Arterioscler Thromb Vasc Biol 1995; 15: 562–570.
Fogelberg M, Bjiorkhem I, Diczfalusy U, Henriksson P . Stanozolol and experimental atherosclerosis: atherosclerotic development and blood lipids during anabolic steroid therapy of New Zealand white rabbits. Scand J Clin Lab Invest 1990; 50: 693–696.
Chen SJ, Li HB, Durand Joparil S, Chen YF . Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation 1996; 93: 577–584.
Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JN, Legros JJ et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int J Androl 2005; 28: 125–127.
Aversa A, Isidori AM, Greco EA, Giannetta E, Gianfrilli D, Spera E et al. Hormonal supplementation and erectile dysfunction. Eur Urol 2004; 45: 535–538.
Rosano GC . Androgens and coronary artery disease. A sex specific effect of sex hormones? Eur Heart J 2000; 21: 868–871.
Negri M, Sheiban I, Arigliano PL, Tonni S, Montresor G, Carlini S et al. Interrelation between angiographic severity of coronary artery disease and plasma levels of insulin, C-peptide and plasminogen activator inhibitor-1. Am J Cardiol 1993; 72: 397–401.
Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A et al. Effects of testosterone on body composition, serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol 2005; 63: 280–293.
Kloner RA, Mullin SH, Shook T, Matthews R, Mayeda G, Burstein S et al. Erectile dysfunction in the cardiac patient: how common and should we treat? J Urol 2003; 170 (Part 2): S46–S50.
Hak AE, Witteman JCM, de Jong FH, Geerlings MI, Hofman A, Pols HAP . Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: The Rotterdam Study. J Clin Endocrinol Metab 2002; 87: 3632–3639.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rosano, G., Sheiban, I., Massaro, R. et al. Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res 19, 176–182 (2007). https://doi.org/10.1038/sj.ijir.3901504
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijir.3901504
Keywords
This article is cited by
-
Sex steroid and cognitive function among community-dwelling older men with or without vascular risk factors: a cross-sectional study
BMC Geriatrics (2024)
-
Sex differences in cardiovascular risk factors for myocardial infarction
Herz (2021)
-
Pathophysiological effects of androgens on the female vascular system
Biology of Sex Differences (2020)
-
Vascular Pathways of Testosterone: Clinical Implications
Journal of Cardiovascular Translational Research (2020)
-
Different gut microbiome composition in obese Guizhou minipigs between female and castrated male
Folia Microbiologica (2019)